Axsome Therapeutics Presents Solriamfetol Data Showing Cognitive Improvement in Sleep Apnea and Narcolepsy at SLEEP 2024

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, has announced its participation in the SLEEP 2024 conference. The event, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), will take place from June 1-5, 2024, in Houston, Texas. Axsome will present five studies on solriamfetol, including two featured oral plenary sessions.

Solriamfetol is being investigated for its potential benefits in addressing cognitive impairments linked to excessive daytime sleepiness (EDS) and obstructive sleep apnea (OSA). According to Hans Van Dongen, PhD, Professor at Washington State University, solriamfetol has shown promise in enhancing cognitive functions such as executive function, memory, and processing speed.

The first highlighted presentation is titled "Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition." This plenary session, led by Hans Van Dongen, will take place on June 4 from 9:15-9:30 a.m. Central Time. The associated poster session is scheduled for June 5 from 11-11:45 a.m. Central Time.

Another key plenary session, "Effects of Solriamfetol on Cognition in Patients with Excessive Daytime Sleepiness Associated with Narcolepsy," will be presented by Yaroslav Winter, MD, from Johannes Gutenberg-University in Mainz, Germany. This session will occur on June 4 from 5-5:15 p.m. Central Time, with a poster session on June 3 from 11-11:45 a.m. Central Time.

Additional presentations include:

- "Solriamfetol and Maintenance of Wakefulness Outcomes in Patients with Narcolepsy and Obstructive Sleep Apnea," led by Dr. Michael Thorpy of Montefiore Medical Center. The poster session is scheduled for June 4 from 11-11:45 a.m. Central Time.
- "Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression," presented by Ulf Kallweit, Assistant Professor of Neurology at the University Witten/Herdecke, Germany. The poster session will be on June 5 from 11-11:45 a.m. Central Time.
- "SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes," led by Samantha Floam, DMD, from Axsome Therapeutics. This poster session will be held on June 4 from 10-10:45 a.m. Central Time.

Axsome Therapeutics is dedicated to advancing treatment options for CNS disorders, which often have limited therapeutic solutions. Their commitment to innovative therapies aims to significantly improve patient outcomes and provide new options for healthcare providers.

The company is also focused on the ongoing commercial success of its products, Sunosi® and Auvelity®, while actively pursuing new indications for solriamfetol and AXS-05. Axsome continues to advance its clinical trials, with the goal of expanding its portfolio and securing regulatory approvals for additional therapeutic uses.

In summary, Axsome's participation in SLEEP 2024 underscores its commitment to addressing cognitive impairments associated with sleep disorders. Through its presentations, the company aims to highlight the potential of solriamfetol in improving cognitive functions and overall patient quality of life.